R&D

Neutralizing antibodies in the battle against COVID-19

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection. A team of researchers led by Prof. Florian Klein (Cologne University Hospital) and the German Center for Infection Research (DZIF) has further elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies.

Using Epo against COVID-19

Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against COVID-19. The growth factor could mitigate severe disease progression and protect patients from long-term neurological effects when the Sars-CoV-2 virus attacks the brain.

Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction

SARS-CoV-2, the coronavirus causing the global COVID-19 pandemic, uses a protein called polymerase to replicate its genome inside infected human cells. Terminating the polymerase reaction will stop the growth of the coronavirus, leading to its eradication by the human host's immune system.

Whole-town study reveals more than 40% of COVID-19 infections had no symptoms

A study of COVID-19 in the quarantined Italian town of Vò, where most of the population was tested, reveals the importance of asymptomatic cases.

The authors of the new research, from the University of Padova and at Imperial College London, published today in Nature, suggest asymptomatic or pre-symptomatic people are an important factor in the transmission of COVID-19.

Existing drugs can prevent SARS-CoV-2 from hijacking cells

An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells. The research, published in the journal Cell, shows how the virus shifts the cell's activity to promote its own replication and to infect nearby cells. The scientists also identified seven clinically approved drugs that could disrupt these mechanisms, and recommend that these drugs are immediately tested in clinical trials.

Initial COVID-19 infection rate may be 80 times greater than originally reported

Many epidemiologists believe that the initial COVID-19 infection rate was undercounted due to testing issues, asymptomatic and alternatively symptomatic individuals, and a failure to identify early cases.

Now, a new study from Penn State estimates that the number of early COVID-19 cases in the U.S. may have been more than 80 times greater and doubled nearly twice as fast as originally believed.

Researchers identify potent antibody cocktail to treat COVID-19

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published in the journal Science.

Research & Development

Neutralizing antibodies in the battle against COVID-19

Using Epo against COVID-19

Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction

Whole-town study reveals more than 40% of COVID-19 infections had no symptoms

Existing drugs can prevent SARS-CoV-2 from hijacking cells

Initial COVID-19 infection rate may be 80 times greater than originally reported

Researchers identify potent antibody cocktail to treat COVID-19

More Pharma News ...